NuCana reported encouraging results for NUC-7738 and NUC-3373 in recent clinical trials, with financial updates and a projected cash runway.Quiver AI SummaryNuCana plc announced encouraging Phase 2 results...
EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022,...
NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates...
EDINBURGH, United Kingdom, June 03, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification...
Initiated Randomized Phase 2 Study of NUC-3373 in Patients with Colorectal Cancer Initiated Phase 1b/2 Study of NUC-3373 in Combination with Other...
EDINBURGH, United Kingdom, June 01, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host...
Optimizes Development Strategy with Study Initiations and Data Announcements Expected throughout 2022 Announces Plan to Initiate Randomized Phase 2 Study...
Checkpoint Inhibitor Nivolumab Activity Enhanced by NUC-3373 in vitro NUC-3373 Shown to be a More Efficient DNA Damaging Agent in Cancer Cells than 5-FU ...
Independent Data Monitoring Committee Recommended Study be Discontinued Following Futility Assessment Conducted at First Interim Analysis NUC-3373...
EDINBURGH, United Kingdom, Feb. 28, 2022 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and...